Childhood Cancer Research

You are here

Efficient Derivation of Isogenic Hepatoblastoma Cell Lines Bearing Genetically-Defined Driver Mutations

Hepatoblastoma (HB) is the most common pediatric liver cancer and can be classified into several different types. In mice, HBs can be generated by overexpressing in their livers any pairwise or triple combination of three genes that are commonly deregulated in human HBs: ?-catenin (B), YAP (Y) and NRF2 (N). The 4 resulting tumor types (BY, BN, YN and BYN) share many features with human tumors and are currently the best animal surrogates for human HB. Unfortunately, we are hampered by a lack of established HB cell lines from either humans or mice that could otherwise facilitate many critical studies. We have recently discovered that immortalized HB cell lines can be easily established from primary murine HBs by concurrently inactivating gene known as Cdkn2a that normally functions to suppress the growth of many tumor types, including HB. Thus far, 8 BY, 3 BYN, 1 BN and 1 YN cell line have been generated and 12 can be re-grown as under the skin or in the lungs. Moreover, under certain conditionsthese cell lines appear to be able to assume the appearance and function of blood vessel-forming cells known as endothelial cells that are known to facilitate tumor growth by of providing a source of oxygen and nutrients necessary for growth. Molecularly defined HB cell lines will allow us to address several important questions. These include whether tumors generated by different combinations of driver oncogenes utilize similar molecular strategies to generate endothelial cells.

Project Goals

We wish to complete the development of a panel of molecularly defined mouse HB cell lines generated by all possible combinations of the three genes that are most commonly associated with human HBs. Our preliminary studies have already revealed that such tumors possess distinct features and behaviors and that the immortalized cell lines derived from them retain these. Our work will provide the HB research community with a panel of novel HB cell lines for addressing such important question as whether our current chemotherapeutic approaches, that utilize the same drug combinations for all patients, are truly the most effective against all molecular subtypes or whether different or newer combinations of drugs might be more effective against certain subtypes of HB. The cell lines will also be useful in determining the strategies used by HB tumors to develop a blood supply that is critical to their access to the oxygen and nutrients needed for their continued growth.

Project Type
Cancer Research Categories
Date Funded
2025

Project Team

University of Pittsburgh